Evans syndrome occurring in a patient with common variable immunodeficiency (CVID) requires a carefully adapted management strategy. The presence of CVID changes which interventions are appropriate, particularly given the heightened susceptibility to serious infection.
This protocol is for Evans syndrome in the setting of common variable immunodeficiency. Because CVID profoundly affects immune function, the standard approach to Evans syndrome must be modified — the underlying immune deficiency is a central consideration in every treatment decision, including which options are safe and which are contraindicated.
Management in this setting involves a corticosteroid-sparing second-line option combined with systematic immunoglobulin replacement to address infection risk arising from the underlying CVID. Certain surgical interventions that may be considered in primary Evans syndrome are not recommended when CVID is present.
For SLE or CVID-associated ES, the initial strategy is similar to the one of the primary ES, rituximab being a good corticosteroid-sparing 2nd line option while splenectomy is not recommended in those settings.
When rituximab is given for treating a patient with ES who has an underlying CVID, replacement therapy with subcutaneous Ig must be systematic to avoid severe infections.
View source ↗